BRIM Biotechnology Inc.
BRIM Biotechnology, Inc., a clinical-stage company, engages in the development of novel regenerative therapies to combat and cure ophthalmology and degenerative joint diseases. The company's lead product candidate is BRM 421, a topical ophthalmic solution for patients with moderate-to-severe dry eye syndrome that has completed a phase 2 clinical trial in the United States. It is also developing B… Read more
BRIM Biotechnology Inc. (6885) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2024: -0.060x
Based on the latest financial reports, BRIM Biotechnology Inc. (6885) has a cash flow conversion efficiency ratio of -0.060x as of June 2024.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-97.03 Million) by net assets (NT$1.62 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
BRIM Biotechnology Inc. - Cash Flow Conversion Efficiency Trend (2019–2023)
This chart illustrates how BRIM Biotechnology Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
BRIM Biotechnology Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of BRIM Biotechnology Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Lechwerke AG
F:LEC
|
0.109x |
|
Smartbroker Holding AG
XETRA:SB1
|
-0.051x |
|
RENOLD PLC LS-05
F:7M5
|
N/A |
|
Anderson Industrial Corp
TW:1528
|
0.021x |
|
Safkar Ege Sogutmacilik Klima Soguk Hava Tesisleri Ihracat Ithalat Sanayi ve Tic
IS:SAFKR
|
0.024x |
|
A.L.A. S.P.A. O.N.
F:8WD
|
N/A |
|
Prairie Operating Co. Common Stock
OTCQB:PROP
|
-0.077x |
|
NAFCO CO. LTD.
F:64E
|
N/A |
Annual Cash Flow Conversion Efficiency for BRIM Biotechnology Inc. (2019–2023)
The table below shows the annual cash flow conversion efficiency of BRIM Biotechnology Inc. from 2019 to 2023.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-12-31 | NT$1.74 Billion | NT$-596.89 Million | -0.344x | -82.93% |
| 2022-12-31 | NT$914.69 Million | NT$-171.87 Million | -0.188x | +20.23% |
| 2021-12-31 | NT$477.89 Million | NT$-112.57 Million | -0.236x | +51.11% |
| 2020-12-31 | NT$263.82 Million | NT$-127.12 Million | -0.482x | -81.58% |
| 2019-12-31 | NT$429.83 Million | NT$-114.06 Million | -0.265x | -- |